Ceftobiprole medocaril

Drug Profile

Ceftobiprole medocaril

Alternative Names: BAL-5788; BAL-9141; Ceftobiprole; Ceftobiprole medocaril sodium; JNJ 30982081; Mabelio; RO-65-5788; Zeftera; Zevtera

Latest Information Update: 21 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Basilea Pharmaceutica
  • Developer Basilea Pharmaceutica; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson Pharmaceutical Research & Development
  • Class Antibacterials; Cephalosporins; Skin disorder therapies; Small molecules
  • Mechanism of Action Cell wall inhibitors; Peptidyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia; Nosocomial pneumonia
  • No development reported Paediatric infections; Skin and soft tissue infections

Most Recent Events

  • 14 Jun 2017 Ceftobiprole medocaril is available for licensing in Europe as of 21 Jun 2017. http://www.basilea.com/
  • 14 Jun 2017 Ceftobiprole medocaril licensed to Avir Pharma for commercialisation in Canada
  • 27 Apr 2017 Basilea Pharmaceutica and Department of Health and Human Services plan a phase III trial for Bacterial skin and Skin structure infections (IV) (NCT03137173)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top